Clinical Trial Update: A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating once-daily low and high dose solabegron versus placebo for 12 weeks in women with overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Solabegron (solabegron)

Snippet

Sponsor: Velicept Therapeutics, Inc. | Conditions: Overactive Bladder | Phase 2 | Status: COMPLETED